ReviewFrontiers in pharmacology2014
Challenges and future prospects of antibiotic therapy: from peptides to phages utilization.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 153 citations in OpenAlex.
- Unlocking the potential of cyclic peptides in bioactive wound dressings for enhanced tissue repair.Molecular biology reports · 2026Review
- Antibiofilm efficacy and genomic characterization of a lytic bacteriophage targeting MDR uropathogenic Escherichia coli.Archives of microbiology · 2026Article
- A novel jumbo phage infecting Pseudomonas aeruginosa: genomic insights and phylogenetic classification.Archives of microbiology · 2026Article
- Nrf2 activator peptide protects the brain from cerebral vascular dysfunction in alcohol ingestion.JCI insight · 2026Article
- Efficacy of a novel bacteriophage in controlling Escherichia coli associated with swine farm environments and its potential for biofilm disruption.Scientific reports · 2026Article
- Genomic and functional characterization of a lyticFrontiers in microbiology · 2026Article
- Turning Waste into Treasure: Functionalized Biomass-Derived Carbon Dots for Superselective Visualization and Eradication of Gram-Positive Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Design of Natterins-based peptides improves antimicrobial and antiviral activities.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Unraveling the treasure trove of phytochemicals in mitigating the Salmonella enterica infection.Folia microbiologica · 2025Review
- Synthesis, Characterization, and Antimicrobial Activity of Urea-Containing α/β Hybrid Peptides againstACS omega · 2025Article
- Surface-enhanced Raman spectroscopy for the characterization of bacterial pellets ofRSC advances · 2024Article
- Discovery of novel antibacterial agent for the infected wound treatment: all-hydrocarbon stapling optimization of LL-37.Theranostics · 2024Article
- Resensitisation of Methicillin-ResistantPharmaceutics · 2023Article
- Characterization of two novel lytic bacteriophages having lysis potential against MDR avian pathogenic Escherichia coli strains of zoonotic potential.Scientific reports · 2023Article
- Antioxidant Efficacy of Green-Synthesized Silver Nanoparticles Promotes Wound Healing in Mice.Pharmaceutics · 2023Article
- Synergistic Antimicrobial Activity of Ceftriaxone andAntibiotics (Basel, Switzerland) · 2023Article
- IgY antibodies: The promising potential to overcome antibiotic resistance.Frontiers in immunology · 2023Review
- Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles.Pathogens and global health · 2022Article
- Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Antimicrobial Peptides: Bringing Solution to the Rising Threats of Antimicrobial Resistance in Livestock.Frontiers in veterinary science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infections are raising serious concern across the globe. The effectiveness of conventional antibiotics is decreasing due to global emergence of multi-drug-resistant (MDR) bacterial pathogens. This process seems to be primarily caused by an indiscriminate and inappropriate use of antibiotics in non-infected patients and in the food industry. New classes of antibiotics with different actions against MDR pathogens need to be developed urgently. In this context, this review focuses on several ways and future directions to search for the next generation of safe and effective antibiotics compounds including antimicrobial peptides, phage therapy, phytochemicals, metalloantibiotics, lipopolysaccharide, and efflux pump inhibitors to control the infections caused by MDR pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.